

## In brief

### Omicron BA.2 sub-lineage

18 March 2022

---

### Summary

- Omicron (B.1.1.529) was designated a variant of concern by the [World Health Organization \(WHO\)](#) on 26 November 2021. It has 50 mutations, including [26-32 mutations on its spike protein](#).<sup>1,2</sup>
- [Omicron includes four Pango lineages](#): the parental B.1.1.529 and the descendent lineages BA.1, BA.2 and BA.3. WHO is monitoring all variants under [Omicron](#).<sup>2,3</sup>
- The spike profile of [BA.2 contains 28 mutations](#) and a deletion at 25-27.<sup>4</sup>
- WHO recommends that [investigations into the characteristics of BA.2](#), including immune escape properties and virulence, should be prioritised independently (and comparatively) to BA.1.<sup>5</sup>
- While BA.1 has previously been the most dominant strain, BA.2 is increasing and is dominant in several countries.<sup>2</sup>
- WHO released [interim guidance on contact tracing and quarantine](#) for Omicron.<sup>6</sup>

### Transmissibility

- The United Kingdom Health Security Agency (UKHSA) Variant Technical Group designated BA.2 as a 'variant under investigation' on 19 January 2022.<sup>2,4</sup> A [risk assessment](#) updated by the agency on 23 February 2022 reported moderate confidence level risk for overall growth advantage, low confidence level risk for transmissibility, and moderate confidence risk for immune evasion and infection severity.<sup>7</sup> The [WHO used the UKHSA framework to conduct a risk assessment](#) which reported moderate confidence level risk for transmissibility, low confidence risk for disease severity, moderate for immune escape and low for impact on detection capacity. There was insufficient data on differences in effectiveness of current treatments between BA.2 and other lineages.<sup>8</sup>
- Early reports suggest BA.2 has an [increased growth rate compared to BA.1](#). Preliminary data from Denmark suggests BA.2 may be [1.5 times more transmissible than BA.1](#).<sup>9,10</sup>
- BA.2 appears to be more infectious than BA.1 ([higher viral loads and longer infectious periods](#)).<sup>11</sup>
- One study suggests the [within-round reproduction number](#) (R) is 0.94. The R additive advantage for BA.2 (vs BA.1 or BA.1.1) was estimated to be 0.40.<sup>12</sup> Other estimates suggests the reproduction number of BA.2 is 1.4-fold higher than BA.1,<sup>13</sup> and that the reproductive number of BA.1 is 1.99 times and that of [BA.2 is 2.51](#) times larger than the effective reproduction number of Delta.<sup>14</sup>
- Preliminary analysis suggests a [mean serial interval of 3.27 days compared to 3.72 days for BA.1](#). Both are shorter than the mean serial interval for Delta of 4.09 days.<sup>13</sup>
- Preliminary analysis from the UKHSA suggests a 13.4% secondary attack rate for BA.2 compared to 10.3% for other Omicron cases.<sup>9</sup> Estimates from Denmark are [29% and 39% in households with BA.1 and BA.2](#), respectively, and data suggests increased transmissibility from unvaccinated primary cases in BA.2 households.<sup>15</sup>

### Severity

- Early data from Denmark suggests there is [no difference in the risk of hospital admissions](#) between BA.1 and BA.2.<sup>16</sup>

- One study assessed the severity of [BA.2 infections compared to BA.1 in South Africa](#). Findings suggest that while BA.2 may have a competitive advantage over BA.1 in some settings, the clinical profile of the illness remains similar.<sup>17</sup>

### COVID-19 vaccines

- Early assessments do not suggest a difference in vaccine effectiveness against symptomatic disease for BA.2 compared to BA.1. Preliminary unpublished data from the University of Oxford found BA.1 and BA.2 pseudoviruses did not differ substantially in neutralisation by sera from vaccinated individuals. Another study suggests [vaccine effectiveness](#) against symptomatic disease is similar for BA.1 and BA.2; reporting that 25 plus weeks after two doses vaccine effectiveness was 9% and 13% respectively for BA.1 and BA.2. At two weeks following a booster vaccine, effectiveness was 63% for BA.1 and 70% for BA.2.<sup>9, 18</sup>
- Estimated vaccine [effectiveness of Comirnaty against symptomatic infection](#) for BA.1 is 46.6% and for BA.2 is 51.7% in the first three months, both with a decline to approximately 10% thereafter.<sup>19</sup>
- Reports suggest [vaccine-induced humoral immunity fails to function against BA.2 like BA.1](#), and notably, the antigenicity of BA.2 is different from BA.1. Infection experiments using hamsters show that BA.2 is more pathogenic than BA.1.<sup>13</sup>

### Reinfection

- [Early evidence suggests BA.2 reinfections](#) occur shortly after BA.1 infections, however reinfection is rare. Findings from a study in Denmark identified 47 instances of BA.2 reinfection after a BA.1 infection, mostly in unvaccinated individuals with mild disease not resulting in hospitalisation or death.<sup>20</sup> Another study suggests the protective effectiveness of [BA.1 infection against reinfection with BA.2](#) is estimated at 94.9%.<sup>21</sup>
- Reports of [co-infections and infection by Delta-Omicron recombinant](#) virus in several countries.<sup>22</sup>

### Monoclonal antibodies

- Preliminary studies suggest BA.2 exhibits [marked resistance to monoclonal antibodies](#), including [sotrovimab](#), which retained neutralising activity against BA.1.<sup>23, 24</sup>
- One study, comparing the [sensitivity of BA.1 and BA.2](#) to neutralisation by nine monoclonal antibodies, suggests BA.2 was sensitive to cilgavimab, partly inhibited by imdevimab and resistant to adintrevimab and sotrovimab. Anti-Omicron activity of Ronapreve, and to a lesser extent that of Evusheld, is reduced in patients' sera, which is associated with decreased clinical efficacy.<sup>25</sup>
- The United States Food and Drug Administration issued an emergency use [authorisation for bebtelovimab](#) on 11 February 2022. Laboratory testing suggests the [monoclonal antibody retained activity](#) against BA.2.<sup>26, 27</sup>

### Diagnosis

- BA.2 does not contain the deletion at S:69-70 and is S-gene target positive on polymerase chain reaction (PCR) diagnostic assays. [UKHSA suggests that S-gene target failure](#) is no longer sufficient to assess the spread of Omicron as a whole.<sup>4, 9</sup> [N-gene target failure](#) can detect BA.2.<sup>28</sup>
- Results for rapid testing are conflicting, with some studies showing a reduced detection rate of Omicron infections, however a study from the United States showed comparable sensitivity between Omicron and Delta.<sup>29, 30</sup> It is [difficult to predict](#) the test performance specific to BA.2.<sup>31</sup>

## References

1. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern [Internet]. Switzerland: WHO; 26 Nov 2021 [cited 3 Dec 2021]. Available from: [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).
2. World Health Organization. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States [Internet]. Switzerland: WHO; 21 Jan 2022 [cited 27 Jan 2022]. Available from: [https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-\(b.1.1.529\)-technical-brief-and-priority-actions-for-member-states](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states).
3. World Health Organization. Weekly epidemiological update on COVID-19 - 25 January 2022 [internet] Switzerland: WHO; 25 Jan 2022 [cited 31 Jan 2022] Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-january-2022>.
4. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 34 [Internet]. England: UK Health Security Agency; 14 Jan 2022 [cited 19 Jan 2022]. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1046853/technical-briefing-34-14-january-2022.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1046853/technical-briefing-34-14-january-2022.pdf).
5. World Health Organization. Tracking SARS-CoV-2 variants [internet] Switzerland: WHO; Jan 2022 [cited 31 Jan 2022] Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>.
6. World Health Organisation. Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance [internet] Switzerland: WHO; 28 Feb 2022 [cited 17 March 2022] Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-Contact-tracing-and-quarantine-Omicron-variant-2022.1>.
7. UK Health Security Agency. Risk assessment for SARS-CoV-2 variant: VUI-22JAN-01 (BA.2) [internet] United Kingdom: UKHSA; 23 Feb 2022 [cited 17 March 2022] Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1057361/23-February-2022-risk-assessment-for-VUI-22JAN-01\\_BA.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1057361/23-February-2022-risk-assessment-for-VUI-22JAN-01_BA.pdf).
8. World Health Organization. Weekly epidemiological update on COVID-19 - 15 February 2022 [internet] Switzerland: WHO; 15 Feb 2022 [cited 18 Feb 2022] Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-february-2022>.
9. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 35 [Internet]. England: UK Health Security Agency; 28 Jan 2022 [cited 31 Jan 2022]. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1050999/Technical-Briefing-35-28January2022.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022.pdf).
10. Steenhuisen J. Explainer: Scientists on alert over rising cases caused by Omicron cousin BA.2 [internet] United States: Reuters; 31 Jan 2022 [cited 31 Jan 2022] Available from: <https://www.reuters.com/business/healthcare-pharmaceuticals/scientists-alert-over-rising-cases-caused-by-omicron-cousin-ba2-2022-01-30/>.
11. Qassim SH, Chemaitelly H, Ayoub HH, et al. Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections. medRxiv. 2022:2022.03.02.22271771. DOI: 10.1101/2022.03.02.22271771
12. Chadeau-Hyam M, Tang D, Eales O, et al. The Omicron SARS-CoV-2 epidemic in England during February 2022. medRxiv. 2022:2022.03.10.22272177. DOI: 10.1101/2022.03.10.22272177
13. Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of SARS-CoV-2 BA.2 variant. bioRxiv. 2022:2022.02.14.480335. DOI: 10.1101/2022.02.14.480335

14. Ito K, Piantham C, Nishiura H. Estimating relative generation times and relative reproduction numbers of Omicron BA.1 and BA.2 with respect to Delta in Denmark. medRxiv. 2022:2022.03.02.22271767. DOI: 10.1101/2022.03.02.22271767
15. Lyngse FP, Kirkeby CT, Denwood M, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. medRxiv. 2022:2022.01.28.22270044. DOI: 10.1101/2022.01.28.22270044
16. European Centre for Disease Prevention and Control. Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU/EEA, 19th update [Internet]. Europe: ECDC; 27 Jan 2022 [cited 31 Jan 2022]. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/RRA-19-update-27-jan-2022.pdf>.
17. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa. medRxiv. 2021:2021.12.21.21268116. DOI: 10.1101/2021.12.21.21268116.
18. UK Health Security Agency. COVID-19 vaccine surveillance report. Week 4 [Internet]. England: UK Health Security Agency; 27 Jan 2022 [cited 31 Jan 2022]. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1050721/Vaccine-surveillance-report-week-4.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf).
19. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. medRxiv. 2022:2022.03.13.22272308. DOI: 10.1101/2022.03.13.22272308
20. Stegger M, Edslev SM, Sieber RN, et al. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection. medRxiv. 2022:2022.02.19.22271112. DOI: 10.1101/2022.02.19.22271112
21. Chemaitelly H, Ayoub HH, Coyle P, et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. medRxiv. 2022:2022.02.24.22271440. DOI: 10.1101/2022.02.24.22271440
22. Bolze A, White S, Basler T, et al. Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination. medRxiv. 2022:2022.03.09.22272113. DOI: 10.1101/2022.03.09.22272113
23. Iketani S, Liu L, Guo Y, et al. Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages. bioRxiv. 2022:2022.02.07.479306. DOI: 10.1101/2022.02.07.479306
24. Zhou H, Tada T, Dcosta BM, et al. SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies. bioRxiv. 2022:2022.02.15.480166. DOI: 10.1101/2022.02.15.480166
25. Bruel T, Hadjadj J, Maes P, et al. Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodies. medRxiv. 2022:2022.03.09.22272066. DOI: 10.1101/2022.03.09.22272066
26. U.S. Food & Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant [internet] United States: FDA; 11 Feb 2022 [cited 17 March 2022] Available from: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retain#:~:text=Laboratory%20testing%20showed%20that%20bebtelovimab,severe%20COVID%2D19%20illness.>
27. Zhou H, Tada T, Dcosta BM, et al. Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies. bioRxiv. 2022:2022.02.15.480166. DOI: 10.1101/2022.02.15.480166
28. Harankhedkar S, Chatterjee G, Rajpal S, et al. N Gene Target Failure (NGTF) for detection of Omicron: a way out for the 'stealth' too? medRxiv. 2022:2022.01.28.22269801. DOI: 10.1101/2022.01.28.22269801
29. Soni A, Herbert C, Filippaios A, et al. Comparison of Rapid Antigen Tests' Performance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study. medRxiv. 2022:2022.02.27.22271090. DOI: 10.1101/2022.02.27.22271090

30. Bekliz M, Adea K, Alvarez C, et al. Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron variant. medRxiv. 2021:2021.12.18.21268018. DOI: 10.1101/2021.12.18.21268018
31. Osterman A, Badell I, Basara E, et al. Impaired detection of omicron by SARS-CoV-2 rapid antigen tests. Medical Microbiology and Immunology. 2022 2022/02/20. DOI: 10.1007/s00430-022-00730-z

SHPN:(ACI) 220206 | TRIM: ACI/D22/51-07 | Edition 3